After Cologuard first debuted more than 10 years ago, the new version of the stool test with at-home sample collection brings a refined slate of genetic biomarkers, which the company says cuts its rate of false positives.
First developed through a collaboration with the Mayo Clinic, the test was acquired through the company’s $21 billion buyout of Exact Sciences last year, which also brought the tissue- and blood-based cancer diagnostics Oncotype Dx, Cancerguard and Oncodetect into Abbott’s fold.